Company: HQL
Filing Date: 2025-06-09
Form Type: N-CSRS
Source: 0001104659-25-057746
Chunk: 30

Company: abrdn Life Sciences Investors
Filing Date: 2025-06-09
Form: N-CSRS
Chunk 30
---
 March 31, 2025, were as follows:

| Tax Cost of  
 Securities   |   Unrealized 
 Appreciation | Unrealized     
 Depreciation   | Net            
 Unrealized     
 Appreciation/  
 (Depreciation) |
| $422,207,071 |  $93,584,417 | $(110,712,020) | $(17,127,603)  |

11. Segment Reporting

In this reporting period, the Fund adopted FASB Accounting Standards Update 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures (“ASU 2023-07”). Adoption of the new standard impacted disclosures only and did not affect the Fund’s financial position nor the results of its operations. Operating segments are components of a public entity that engage in business activities from which it may recognize revenues and incur expenses, have discrete financial information available, and have their operating results regularly reviewed by the public entity’s chief operating decision maker (“CODM”) when assessing segment performance and making decisions about segment resources. The Chief Financial Officer of the Fund acts as the Fund’s CODM. The

| 28 | abrdn Life Sciences Investors |

Notes to Financial Statements (unaudited) (concluded) March 31, 2025 CODM monitors the operating results of the Fund as a whole, and the Fund’s asset allocation is managed in accordance with its Prospectus. The Fund operates as a single operating and reporting segment pursuant to its investment objective and principal investment strategy. The Fund’s portfolio composition, total returns, expense ratios and changes in net assets used by the CODM to assess segment performance and make resource allocations are consistent with the information presented within the Fund's financial statements. Segment assets are reflected on the Fund’s Statement of Assets and Liabilities as “Total Assets” and significant segment expenses are listed on the Statement of Operations. 12. Subsequent Events Based on this evaluation, no disclosures and/or adjustments were required to the financial statements as of March 31, 2025, other than as noted below. On May 9, 2025, the Fund announced that it will pay on June 30, 2025, a stock distribution of US $0.43 per share to all shareholders of record as of May 22, 2025.

| abrdn Life Sciences Investors | 29 |

Dividend Reinvestment and Optional Cash Purchase Plan (Unaudited) The Fund intends to distribute to shareholders substantially all of its net